HDAC6, small molecule, peripheral neuropathy, cardiometabolic, pharmaceuticals, biotech, biopharma, life science
HDAX Therapeutics has raised $3.2M in total funding. The most recent round was Seed. The last funding was announced in September 2024.
HDAX Therapeutics's investors include Ontario Centre of Innovation, FACIT, Anges Quebec, SeedFolio, Toronto Innovation Acceleration Partners.
HDAX Therapeutics is headquartered in Toronto, Canada.
HDAC6, small molecule, peripheral neuropathy, cardiometabolic, pharmaceuticals, biotech, biopharma, life science
HDAX Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HDAX Therapeutics — Funding & Investors." VCBacked, September 5, 2024, https://www.vcbacked.co/company/hdax-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). HDAX Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hdax-therapeutics
{{cite web |title=HDAX Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/hdax-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated